Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn
The transaction follows a sale process initiated by Mitsubishi Chemical Group in September 2024, as reported by Nikkei Asia. In the 7 February announcement, the parent company said that continuous additional investments are essential for enhancing R&D capabilities and achieving further growth. It added that Bain's expertise in healthcare investment was a key reason for its selection, offering Mitsubishi Tanabe 'multifaceted support from a new partner deeply knowledgeable in the pharmaceuticals business'. The deal is expected to close in Q3 2025.
In December 2024, sources told Reuters that private equity firm Blackstone was also interested in a deal for Mitsubishi Tanabe along with Bain, valuing the company at between $3bn and $3.5bn.
Bain life sciences partner Ricky Sun states that Japan's regulatory environment is evolving, with government initiatives aimed at accelerating drug development and approval: 'This is an exciting opportunity to leverage our team's clinical insights and company creation support to build out a scale platform focused on long-term fundamental drug development in areas of significant unmet need to ultimately bring transformative medicines to patients in Japan and globally.'
Mitsubishi Tanabe, based in Osaka, Japan, develops treatments mainly for central nervous system disorders, immuno-inflammation, and oncology. The company has been expanding its pipeline with a number of deals over the last few years. In January 2025, Mitsubishi entered a licensing agreement with Lonza's subsidiary Synaffix to advance antibody-drug conjugate (ADC) programmes. Under the agreement, Synaffix will manufacture ADC-related components while Mitsubishi will oversee the research, development, and commercialisation of the programme. Financial terms for this agreement were not disclosed.
In December 2024, Mitsubishi Tanabe Pharma announced a research collaboration with Boston, Massachusetts-based Dewpoint Therapeutics, with a deal valued for up to $480m. The partnership focuses on a preclinical amyotrophic lateral sclerosis (ALS) programme. Mitsubishi also has its own ALS treatment Radicava (edaravone), which was approved by the US Food and Drug Administration (FDA) in 2017.
Other deals include one with Moderna for mRNA vaccines, and Eli Lilly Japan for the distribution and marketing of its GIP/GLP-1 receptor agonist blockbuster Mounjaro (tirzepatide).
"Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
14 minutes ago
- Chicago Tribune
US pediatricians' new COVID-19 shot recommendations differ from CDC advice
NEW YORK — For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine recommendations. The group's new COVID-19 recommendations — released Tuesday — come amid a tumultuous year for public health, as vaccine skeptics have come into power in the new Trump administration and government guidance has become increasingly confusing. This isn't going to help, acknowledged Dr. James Campbell, vice chair of the AAP infectious diseases committee. 'It is going to be somewhat confusing. But our opinion is we need to make the right choices for children to protect them,' he added. The AAP is strongly recommending COVID-19 shots for children ages 6 months to 2 years. Shots also are advised for older children if parents want their kids vaccinated, the AAP said. That differs from guidance established under U.S. Health Secretary Robert F. Kennedy Jr., which doesn't recommend the shots for healthy children of any age but says kids may get the shots in consultation with physicians. Children ages 6 months to 2 years are at high risk for severe illness from COVID-19, and it was important that recommendations continue to emphasize the need for them to get vaccinated, said Campbell, a University of Maryland infectious diseases expert. Vaccinations also are recommended for older children who have chronic lung diseases or other conditions that put them at higher risk for severe disease, the AAP said. In a statement, Department of Health and Human Services spokesperson Andrew Nixon said 'the AAP is undermining national immunization policymaking with baseless political attacks.' He accused the group of putting commercial interests ahead of public health, noting that vaccine manufacturers have been donors to the AAP's Friends of Children Fund. The fund is currently paying for projects on a range of topics, including health equity and prevention of injuries and deaths from firearms. The 95-year-old Itasca, Illinois-based organization has issued vaccination recommendations for children since the 1930s. In 1995, it synced its advice with recommendations made by the federal government's Centers for Disease Control and Prevention. There have been a few small differences between AAP and CDC recommendations since then. For example, the AAP has advised that children get HPV vaccinations starting at age 9; the CDC says that's OK but has emphasized vaccinations at ages 11 and 12. But in 30 years, this is the first time the recommendations have differed 'in a significant or substantial way,' Campbell said. Until recently, the CDC — following recommendations by infectious disease experts — has been urging annual COVID-19 boosters for all Americans ages 6 months and older. But in May, U.S. Health Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccines are no longer recommended for healthy children and pregnant women. A few days later, the CDC issued language that healthy children may get the shots, but that there was no longer a 'should' recommendation. The idea that healthy older kids may be able to skip COVID-19 boosters has been brewing for some time among public health experts. As the COVID-19 pandemic has waned, experts have increasingly discussed the possibility of focusing vaccination efforts on people 65 and older — who are among those most as risk for death and hospitalization. A CDC expert panel in June was set to make recommendations about the fall shots. Among the options the panel was considering was whether suggest shots for high-risk groups but still giving lower-risk people the choice to get vaccinated. But Kennedy bypassed the group, and also decided to dismiss the 17-member panel and appoint his own, smaller panel, that included vaccine skeptics. Kennedy also later excluded the AAP, the American Medical Association and other top medical organizations from working with the advisers to establish vaccination recommendations. Kennedy's new vaccine panel has yet to vote on COVID-19 shot recommendations. The panel did endorse continuing to recommend fall flu vaccinations, but also made a decision that led to another notable difference with the AAP. The new advisory panel voted that people should only get flu vaccines that are packaged as single doses and do not contain the preservative thimerosal. The AAP said there is no evidence of harm from the preservative, and recommended doctors use any licensed flu vaccine product that's appropriate for the patient.
Yahoo
17 minutes ago
- Yahoo
Maine Trust for Local News workers rally to expand their union
Workers and union organizers walk out of the Portland Press Herald offices in South Portland, Maine on Tuesday, Aug. 19, 2025, to attend a rally in support of expanding their union to cover reporters at other publications run by the Press Herald's parent organization, the Maine Trust for Local News. (Photo by Troy R. Bennett/ Maine Morning Star) About three dozen reporters, photographers, page designers and union activists gathered on a brown lawn adjacent to the Portland Press Herald offices and printing plant Tuesday morning to announce their drive to unionize news workers at all of the Maine Trust for Local News' weekly and daily paper operations around the state. The News Guild of Maine, which is affiliated with the Communications Workers of America, already represents about 150 workers at the Trust's papers and aims to include the 50 or so remaining non-union jobs at the Sun Journal in Lewiston, The Times Record in Brunswick and the Trust's 17 weekly publications. Workers at the daily Kennebec Journal are represented by a separate branch of the CWA and are in the process of merging with the guild. 'More than 70% of those [50 non-union] workers have signed union authorization cards,' said Megan Gray, president of the News Guild of Maine. On Monday, the guild filed a petition with the National Labor Relations Board seeking voluntary union recognition for those workers. The guild has marked the effort as a drive for 'One Big Union.' The nonprofit Trust is the state's largest network of independent news and media outlets. It's a subsidiary of the Colorado-based National Trust for Local News. Management at the Trust has yet to respond to union demands. Messages seeking comment were not immediately returned. Speakers at the union rally expressed concerns about huge pay disparities between publications within the Trust, lack of job security and dwindling local content as papers are forced to work with fewer reporters and share non-local stories. Paul Bagnall, an experienced reporter at The Times Record, said as a non-union worker he makes $18 per hour while starting reporters at the Press Herald earn a minimum of $28.75 per hour. 'With the cost of living going up, my paycheck has already stretched to a breaking point,' Bagnall said. 'I am currently priced out of potential sources of information — going out to events, restaurants and cafes due to the cost of living — and it's still rising.' Joe Lawlor, a longtime Press Herald reporter, called Bagnall's pay shameful. 'We can do better,' Lawlor said. Sophie Burchell, a non-union reporter at the Trust's southern Maine community news division, said her job is unfairly seen as a stepping stone, rather than a sustainable career. 'I want it to be seen as a place people can grow and thrive,' Burchell said. 'I want to see my peers and their talents thrive in Maine journalism.' Kendra Caruso, an education writer at the Sun Journal, said the Trust isn't living up to its own journalism mission. 'Its stated goal is to prevent news deserts across the nation. However, changes the company implemented early this year, including staff layoffs, have only increased the risk of more news deserts in Maine and decreased the amount of local news coming out of our newsrooms across the state,' Caruso said. Gray said there was no way for the Trust to continue to support local journalism without first supporting its local journalists. 'We're expanding our union because we know that we must invest in our workers in order to invest in the future of journalism,' she said. SUPPORT: YOU MAKE OUR WORK POSSIBLE Solve the daily Crossword
Yahoo
17 minutes ago
- Yahoo
Walmart's earnings report will test investor confidence in US market
By Siddharth Cavale NEW YORK (Reuters) -Investors expect Walmart's management to strike a cautious tone on customer demand as the U.S. labor market cools and inflation ticks up, though the company has outperformed its peers over the last year due to its reliance on grocery sales and wealthier customers shopping there more often. Still, analysts say this environment is a sweet spot for Walmart, which reports second-quarter results on Thursday before markets open. Its low-price model and dominance in grocery can help it weather economic storms better than others. The world's largest retailer by sales has surpassed earnings estimates for 11 consecutive quarters, according to LSEG data, sending its valuation soaring even as other consumer staples companies have struggled this year. The Arkansas-based chain's stock has gained nearly 37% in the last 12 months, one of the notable non-tech companies leading a market that has largely sloughed off the effects of U.S. President Donald Trump's ongoing trade war. The broader Consumer Staples sector is up 4.5%, trailing the broad-market S&P 500. The company's May-to-July results are the most closely watched event among this week's retail earnings, following Tuesday's results from Home Depot and Wednesday's reports from Lowe's and Target. Its significance goes beyond retail; as one of the largest and most recognizable companies in the U.S., Walmart is viewed as a barometer for the state of the U.S. consumer. "Walmart essentially is middle America, so I'll be looking for cues from Walmart as to the health of the broader economy," said Charles Sizemore, a Walmart investor. U.S. shoppers remain resilient despite declining sentiment, but they are being increasingly selective about purchases and have shown signs of trading down. RBC Capital Markets analyst Steven Shemesh cautioned that Walmart may adopt a more cautious tone heading into the second half. "The million-dollar question at this point is how customers respond to higher prices. We have seen some higher prices to date, and the consumer has managed through them OK, and we haven't seen a material impact to volume. But I don't think they're very widespread price increases at this point where the consumer has really noticed," Shemesh said. Home Depot missed estimates for quarterly revenue and profit, but kept its annual forecasts intact on Tuesday. Walmart's forward price-to-earnings ratio currently stands at 35.7, compared with an average of 25.5 over the past five years, suggesting investors expect growth. Its market value has soared to about $800 billion, per LSEG Datastream. Investors and analysts expect the retailer to report earnings of 74 cents a share, up nearly 11% from a year ago, and revenue of $176.16 billion, up 4%. Sales fell slightly short of expectations in Walmart's last quarter, but July's retail sales report bolstered analysts' confidence in current spending trends. "July's data showing retail sales grew faster than inflation tells me that the consumer is still spending and unit counts are up," said D.A. Davidson analyst Michael Baker. Reuters' global tariff tracker shows at least 92 out of nearly 300 companies have announced price hikes in response to the trade war, with about one-third from the consumer sectors. That includes Tide detergent and Bounty paper towels maker Procter & Gamble, a top Walmart supplier. "Third quarter is the make-or-break quarter, really, where the higher prices ... are going to be passed along in a more broader way than what we are seeing now," Shemesh said.
